Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Innovative treatments for advanced non-small cell lung cancer
Autore:
Tester, W; Mora, J;
Indirizzi:
Albert Einstein Canc Ctr, Philadelphia, PA 19141 USA Albert Einstein Canc Ctr Philadelphia PA USA 19141 adelphia, PA 19141 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 6, volume: 10, anno: 2001,
pagine: 1021 - 1032
SICI:
1354-3784(200106)10:6<1021:ITFANC>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
COOPERATIVE-ONCOLOGY-GROUP; PHASE-III TRIAL; GEMCITABINE PLUS CISPLATIN; QUALITY-OF-LIFE; RANDOMIZED TRIAL; 2ND-LINE TREATMENT; PREOPERATIVE CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; PACLITAXEL-CISPLATIN; COMPARING CISPLATIN;
Keywords:
chemotherapy; innovative; non-small cell lung cancer;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
102
Recensione:
Indirizzi per estratti:
Indirizzo: Tester, W Albert Einstein Canc Ctr, 5501 Old York Rd, Philadelphia, PA 19141 USA Albert Einstein Canc Ctr 5501 Old York Rd Philadelphia PA USA 19141
Citazione:
W. Tester e J. Mora, "Innovative treatments for advanced non-small cell lung cancer", EXPERT OP I, 10(6), 2001, pp. 1021-1032

Abstract

Lung cancer remains the most frequent and most lethal cancer worldwide. Non-small cell lung cancer (NSCLC) comprises the vast majority of the histological types. Surgery remains the standard therapy for early stage disease but for advanced stage disease, modern treatment is unsatisfactory However, during the past ten years, improvements in response and survival have been seen with the use of newer chemotherapy regimens. Early studies of neoadjuvant (pre-operative) chemotherapy for resectable stage III patients have shown promising results. For patients with non-resectable NSCLC platinum-baseddoublets are now established as first-line treatment, either alone or in combination with radiotherapy. Innovative non-platinum based combinations are actively being evaluated. The most promising non-platinum agents at this time include gemcitabine, paclitaxel, docetaxel, irinotecan and vinore-Ibine. These agents appear to be effective as single agents and in combinationsand also have improved toxicity profiles. Several other systemic approaches are under active evaluation; the most promising areas include anti-angiogenesis agents, immunotoxins, interleukins, vaccines and molecular therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 17:29:44